Business Context and Reporting Period
This Form 8-K is a current report filed by Collegium Pharmaceutical, Inc. on February 22, 2018. The filing addresses a significant legal event involving the company's primary product, Xtampza ER (oxycodone extended-release capsules).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a legal proceeding and does not contain financial statements.
Material Changes and Events
- Patent Infringement Lawsuit: On February 22, 2018, Collegium filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals USA, Inc.
- Triggering Event: The suit was filed in response to a Paragraph IV certification from Teva, indicating Teva submitted an Abbreviated New Drug Application (ANDA) for a generic version of Xtampza ER.
- Patents Involved: The lawsuit alleges infringement of eleven specific U.S. patents listed in the Orange Book for Xtampza ER.
- Legal Consequence: Under the Hatch-Waxman Act, this filing automatically stays or bars the FDA from approving Teva's ANDA for 30 months or until a district court decision adverse to the patents, whichever occurs earlier.
Outlook, Risks, and Management Commentary
Management states that Collegium believes Teva's assertions regarding patent invalidity or non-infringement lack merit and intends to vigorously enforce its intellectual property rights. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to uncertainties.
Identified Risks:
- The ability to successfully enforce intellectual property rights and defend patents.
- The substantial costs associated with defending patent rights in litigation.
- The possibility of generic competition entering the market for Xtampza ER if patents are invalidated or found not infringed.
Investor Verification Checklist
- Verify the status of the eleven specific U.S. patents cited in the lawsuit (Nos. 7,771,707 through 9,763,883).
- Monitor the 30-month stay period on FDA approval for Teva's generic ANDA.
- Review the "Risk Factors" section in Collegium's most recent Form 10-K for detailed disclosures on litigation risks.
- Assess the potential financial impact of litigation costs and the threat of generic competition on future revenue projections.